References
1. Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery.
EMBO Rep. 2004;5(9):837-42.
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical
development success rates for investigational drugs. Nat Biotechnol.
2014;32(1):40-51.
3. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical
industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33.
4. MedicineNet. Drug Approvals - From Invention to Market … A 12-Year
Trip 1999, July 14 [Available from:
https://www.medicinenet.com/script/main/art.asp?articlekey=9877.
5. Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW. The cystic fibrosis
therapeutics development network (CF TDN): a paradigm of a clinical
trials network for genetic and orphan diseases. Adv Drug Deliv Rev.
2002;54(11):1505-28.
6. Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B, et
al. Effect of aerosolized recombinant human DNase on exacerbations of
respiratory symptoms and on pulmonary function in patients with cystic
fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42.
7. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D,
et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a
Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-19.
8. Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic
fibrosis lung disease: selecting the most appropriate agent. Treat
Respir Med. 2005;4(4):255-73.
9. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies
for cystic fibrosis. Clin Chest Med. 2007;28(2):331-46.
10. Chmiel JF, Konstan MW, Elborn JS. Antibiotic and anti-inflammatory
therapies for cystic fibrosis. Cold Spring Harb Perspect Med.
2013;3(10):a009779.
11. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, et
al. A randomized double blind, placebo controlled phase 2 trial of BIIL
284 BS (an LTB4 receptor antagonist) for the treatment of lung disease
in children and adults with cystic fibrosis. J Cyst Fibros.
2014;13(2):148-55.
12. Doring G, Bragonzi A, Paroni M, Akturk FF, Cigana C, Schmidt A, et
al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa
bacteremia and inflammation in mouse lungs. J Cyst Fibros.
2014;13(2):156-63.
13. Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, Joseloff E,
et al. Considerations for the Conduct of Clinical Trials with
Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation
Workshop Report. Ann Am Thorac Soc. 2015;12(9):1398-406.
14. National Institutes of Health. Definitions 2015, April 7
[Available from:
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information/definitions.
15. Cook N, Hansen AR, Siu LL, Abdul Razak AR. Early phase clinical
trials to identify optimal dosing and safety. Mol Oncol.
2015;9(5):997-1007.
16. Goss CH, Kaneko Y, Khuu L, Anderson GD, Ravishankar S, Aitken ML, et
al. Gallium disrupts bacterial iron metabolism and has therapeutic
effects in mice and humans with lung infections. Sci Transl Med.
2018;10(460).
17. Takebe T, Imai R, Ono S. The Current Status of Drug Discovery and
Development as Originated in United States Academia: The Influence of
Industrial and Academic Collaboration on Drug Discovery and Development.
Clin Transl Sci. 2018;11(6):597-606.
18. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright
C, et al. Long-term safety and efficacy of ivacaftor in patients with
cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3,
open-label extension study (PERSIST). The Lancet Respiratory Medicine.
2014;2(11):902-10.
19. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al.
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city
children. N Engl J Med. 2011;364(11):1005-15.
20. NIH Definitions Working Group. Biomarkers and surrogate endpoints in
clinical research: definitions and conceptual model. . In: Downing G,
editor. Biomarkers and Surrogate Endpoints: Clinical Research and
Applications Amsterdam: Elsevier; 2000. p. 1-9.
21. Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F,
et al. Biomarkers for cystic fibrosis drug development. J Cyst Fibros.
2016;15(6):714-23.
22. Mogayzel PJ, Jr., Naureckas ET, Robinson KA, Mueller G, Hadjiliadis
D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic
medications for maintenance of lung health. Am J Respir Crit Care Med.
2013;187(7):680-9.
23. Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N,
VanDevanter DR, et al. Use of ibuprofen to assess inflammatory
biomarkers in induced sputum: Implications for clinical trials in cystic
fibrosis. J Cyst Fibros. 2015;14(6):720-6.
24. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in
clinical trials. Statistics in medicine. 2012;31(25):2973-84.
25. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C, Aitken M.
Developing cystic fibrosis lung transplant referral criteria using
predictors of 2-year mortality. Am J Respir Crit Care Med. 2002;166(12
Pt 1):1550-5.
26. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose
ibuprofen in patients with cystic fibrosis. N Engl J Med.
1995;332(13):848-54.
27. Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA,
et al. Sustained Benefit from ivacaftor demonstrated by combining
clinical trial and cystic fibrosis patient registry data. Am J Respir
Crit Care Med. 2015;192(7):836-42.
28. VanDevanter DR, Konstan MW. Outcome measures for clinical trials
assessing treatment of cystic fibrosis lung disease. Clin Investig
(Lond). 2012;2(2):163-75.
29. Stanojevic S, Ratjen F. Physiologic endpoints for clinical studies
for cystic fibrosis. J Cyst Fibros. 2016;15(4):416-23.
30. Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S, et al.
Risk factors for rate of decline in forced expiratory volume in one
second in children and adolescents with cystic fibrosis. J Pediatr.
2007;151(2):134-9, 9.e1.
31. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel P, Dhainaut J, et
al. One-year outcome after severe pulmonary exacerbation in adults with
cystic fibrosis. Am J Respir Crit Care Med. 2005;171(2):158-64.
32. Britto M, Kotagal U, Hornung R, Atherton H, Tsevat J, Wilmott R.
Impact of recent pulmonary exacerbations on quality of life in patients
with cystic fibrosis. Chest. 2002;121(1):64-72.
33. Vandevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ, Konstan MW.
Design and powering of cystic fibrosis clinical trials using pulmonary
exacerbation as an efficacy endpoint. J Cyst Fibros. 2011;10(6):453-9.
34. Goss C, Burns J. Exacerbations in cystic fibrosis. 1: Epidemiology
and pathogenesis. Thorax. 2007;62(4):360-7.
35. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson
RL, Williams J, et al. Early anti-pseudomonal acquisition in young
patients with cystic fibrosis: rationale and design of the EPIC clinical
trial and observational study’. Contemp Clin Trials. 2009;30(3):256-68.
36. Guidance for industry: patient-reported outcome measures: use in
medical product development to support labeling claims: draft guidance.
Health Qual Life Outcomes. 2006;4:79.
37. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and
Validation of the Cystic Fibrosis Questionnaire in the United States: A
Health-Related Quality-of-Life Measure for Cystic Fibrosis. Chest.
2005;128(4):2347-54.
38. Goss CH, Caldwell E, Gries KC, Leidy NK, Edwards T, Flume PA, et al.
Validation of a novel patient-reported respiratory symptoms instrument
in cystic fibrosis: CFRSD-CRISS. Pediatric Pulmonology.
2013;48(S36):A251.
39. Retsch-Bogart G, Quittner A, Gibson R, Oermann C, McCoy K,
Montgomery A, et al. Efficacy and safety of inhaled aztreonam lysine for
airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-32.
40. Ramsey B, Boat T. Outcome measures for clinical trials in cystic
fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference.
J Pediatr. 1994;124(2):177-92.
41. Stalvey MS, Pace J, Niknian M, Higgins MN, Tarn V, Davis J, et al.
Growth in Prepubertal Children With Cystic Fibrosis Treated With
Ivacaftor. Pediatrics. 2017;139(2).
42. VanDevanter DR, Mayer-Hamblett N. Innovating cystic fibrosis
clinical trial designs in an era of successful standard of care
therapies. Current opinion in pulmonary medicine. 2017;23(6):530-5.
43. VanDevanter DR, Mayer-Hamblett N, Boyle M. Feasibility of
placebo-controlled trial designs for new CFTR modulator evaluation. J
Cyst Fibros. 2017;16(4):496-8.
44. Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR,
Boyle MP, et al. CFTR modulator theratyping: Current status, gaps and
future directions. J Cyst Fibros. 2019;18(1):22-34.
45. Durmowicz AG, Lim R, Rogers H, Rosebraugh CJ, Chowdhury BA. The U.S.
Food and Drug Administration’s Experience with Ivacaftor in Cystic
Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a
Clinical Trial. Ann Am Thorac Soc. 2018;15(1):1-2.
46. Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D,
et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to
<24 months and with a CFTR gating mutation (ARRIVAL): a phase
3 single-arm study. The Lancet Respiratory medicine. 2018;6(7):545-53.
47. Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M.
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years With Cystic Fibrosis
Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2016.
48. Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki
GS, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor
in patients aged 2-5 years with cystic fibrosis and a CFTR gating
mutation (KIWI): an open-label, single-arm study. The Lancet Respiratory
medicine. 2016;4(2):107-15.
49. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et
al. A CFTR potentiator in patients with cystic fibrosis and the G551D
mutation. N Engl J Med. 2011;365(18):1663-72.
50. Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al.
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients
with Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(2):188-97.